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Atrial fibrillation (AF) is the most common sustained 
arrhythmia encountered in clinical practice. It is associated 
with a significant increase in thromboembolic complica-
tions, for example, stroke and thromboembolism. Loss of 
synchrony between atria and ventricles leads to continuous 
atrial and ventricular mechanical dysfunction followed by 
the development of heart failure and decreased functional 
capacity. Patients with AF also report impaired quality of life 
as well as decline in cognitive function, and increased mor-
tality when compared to patients in sinus rhythm.1
Lone AF, defined as AF in younger adults (age below 
60 years) with no clinical history or echocardiographic evi-
dence of concomitant cardiovascular or pulmonary condi-
tions or an acute trigger, represents only a minority of cases 
of arrhythmia. Also given that more and more emerging 
risk factors for AF development have been recognized (e.g., 
obesity, obstructive sleep apnea, strenuous physical activ-
ity, inflammation, and so on), “lone AF” has essentially 
become a diagnosis of exclusion.2,3 Even in such cases, the 
risk of adverse outcomes appeared to be higher compared to 
patients without AF.4
The vast majority of AF cases develop as a consequence 
of pre-existing cardiovascular diseases as well as noncar-
diac conditions, which are associated with structural and 
electrical changes that precipitate the development and 
persistence of AF. Arterial hypertension is highly prevalent 
within the general population and is therefore often pre-
sent concomitantly with AF, as well as sharing a range of 
risk factors.5,6
Despite the availability of diagnostic methods and the 
availability of various antihypertensive drugs, further 
improved awareness of high blood pressure, adherence to 
treatment, and hypertension control is highly relevant for 
many patients.7 Hypertension almost inevitably leads to car-
diovascular diseases (as is the case for coronary artery dis-
ease and heart failure), which strengthens the link between 
hypertension and AF even more.8
In the current review article, we provide an overview of 
the epidemiological parallels between hypertension and AF, 
common pathophysiological pathways, and the implications 
of high blood pressure on outcomes in AF patients in vari-
ous clinical scenarios.
EPIDEMIOLOGY OF HYPERTENSION AND AF: A 1-WAY PATH?
A retrospective analysis of 80 million adults in the United 
States found that the prevalence of hypertension was esti-
mated to be 32.6% between 2009 and 2012.7 There were more 
males suffering from hypertension aged <45  years whilst 
for those ≥65 years of age, the opposite gender relationship 
was observed. Between age 45 and 64  years, prevalence of 
Atrial fibrillation (AF) is the most prevalent sustained arrhythmia found 
in clinical practice. AF rarely exists as a single entity but rather as part 
of a diverse clinical spectrum of cardiovascular diseases, related to 
structural and electrical remodeling within the left atrium, leading 
to AF onset, perpetuation, and progression. Due to the high overall 
prevalence within the AF population arterial hypertension plays a sig-
nificant role in the pathogenesis of AF and its complications. Fibroblast 
proliferation, apoptosis of cardiomyocytes, gap junction remodeling, 
accumulation of collagen both in atrial and ventricular myocardium all 
accompany ageing-related structural remodeling with impact on elec-
trical activity. The presence of hypertension also stimulates oxidative 
stress, systemic inflammation, rennin–angiotensin–aldosterone and 
sympathetic activation, which further drives the remodeling process in 
AF. Importantly, both hypertension and AF independently increase the 
risk of cardiovascular and cerebrovascular events, e.g., stroke and myo-
cardial infarction. Given that both AF and hypertension often present 
with limited on patient wellbeing, treatment may be delayed result-
ing in development of complications as the first clinical manifestation 
of the disease. Antithrombotic prevention in AF combined with strict 
blood pressure control is of primary importance, since stroke risk and 
bleeding risk are both greater with underlying hypertension.
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hypertension in males and females remains approximately 
similar.7
The National Health and Nutrition Examination Survey 
in 2011–2012 found that 17.2% of adults in the United 
States are unaware they have high blood pressure; also, 
over 10% of hypertensive patients failed to reach target 
blood pressure despite use of ≥4 drugs from 3 different 
drug classes, i.e., resistant hypertension.7 The prevalence 
of hypertension demonstrates an increasing trend over 
past decades, and projections showed further anticipated 
increases up to 41.4%.7 In the elderly, its prevalence is even 
higher (65.0% among US adults 60 years of age or older) 
with a higher percentage receiving treatment (86.1%) but 
a lower proportion of patients achieve blood pressure con-
trol (50.5%).7
The rising prevalence of hypertension is associated with 
increases in overall mortality. Life expectancy of normoten-
sive individuals is approximately 5 years higher than in their 
hypertensive counterparts. Indeed, there were over 70,000 
deaths attributable to hypertension that equated to a death 
rate of 19.9 in 2013. Amongst cardiovascular risk factors 
hypertension is the leading cause of death in females and 
only second after smoking as the cause of death in males. Of 
note, cardiovascular diseases are likely to occur 7 years later 
on a background of normal blood pressure.7
Unfortunately, reliable data from the developing as well 
as low- and middle-income countries are more scarce com-
pared to developed high-income countries, and variability 
in studies design, population selection, methodology, and so 
on make direct comparison of the data hard to interpret.9 
Overall, there have been global disparities in hypertension 
prevalence and control.9,10 Reported prevalence is higher 
in low- and middle-income countries than in high-income 
countries, while hypertension awareness, treatment, and 
control were much lower in low- and middle-income than 
in high-income countries.10 Furthermore, the larger grow-
ing populations in developing countries make a greater 
impact upon the global burden of hypertension.9 One of 
reasons for the increasing hypertension prevalence is major 
achievements in prevention and treatment of cardiovascular 
diseases leading to improved survival, increased life expec-
tancy, and therefore an ageing population.11
Such trends are evident for AF epidemiology. In the 
Framingham Heart Study of over 200 thousand person-
years, age-adjusted AF prevalence increased 4-fold from 20.4 
to 96.2 cases and 13.7 to 49.4 cases per 1,000 person-years 
in males and females, respectively.12 A  similar trend was 
apparent for the age-adjusted AF incidence that increased 
from 3.7 to 13.4 cases per 1,000 person-years and 2.5 to 8.6 
cases in males and females, respectively.12 Furthermore, 
AF prevalence and incidence also show age-dependency. 
In the Rotterdam Study, for example, the prevalence of AF 
was 1.3% in men and 1.7% in women in patients aged of 55 
to 59  years, but reached 24.2% and 16.1%, respectively, in 
those who were older than 85 years of age.13 Lifetime risks 
for development of AF were approximately 1 in 4 in both 
the Framingham Heart Study (age of 40 years and older) and 
Rotterdam Study (age of 55 years and older).14,15
According to the global burden of disease study pub-
lished in 2014, over 20 million males and 12 million females 
were estimated to suffer from AF worldwide, and close to 5 
million new AF cases were added to AF burden annually.16 
During the 2 past decades AF-associated health burden 
evaluated with the disability adjusted life-years, increased 
by approximately 19%.16 The estimated age-adjusted AF 
prevalence and incidence rates increased by 26.7 and 16.8 
per 100,000 person-years in males as well as 13.2 and 15.7 
per 100,000 person-years in females, respectively.16 Western 
developed countries, i.e., United States and European 
Union, are major contributor to the global burden of AF, 
with approximately 8 and 9 million AF cases estimated.13,16 
The prevalence and incidence of AF in developing coun-
tries is likely to be lower, and also varies between developed 
countries.17,18
When current trends in the incidence and prevalence of 
AF (derived in the Olmsted County cohort) were applied, the 
projected number of AF cases by the year of 2050 is likely to 
increase 2–3 fold with 35% of new patients with AF attrib-
uted to growing AF incidence while another 65%—due to 
increase in population size, largely explained by increased 
survival accompanied by shift in age distribution (less due 
to population expansion itself).19,20 In European countries, if 
the trends from the Rotterdam study remain, the numbers of 
individuals with AF is projected to double by 2060.13
Accurate assessment of AF epidemiology is subject to bias 
because of the absence of population-based data in many 
countries and peculiarities with regards to the clinical course 
of AF, for example, asymptomatic (silent) AF or those pre-
senting with very short intermittent episodes.
Single time-point screening for AF via pulse palpation or 
short-term electrocardiogram recording was capable of iden-
tifying AF in as much as 1% of the screened population with 
previously unknown AF. This increased when subgroup of 
elder patients (e.g., 65 years of age or older) was chosen.21,22 
The probability of catching the episode of paroxysmal AF 
correlates with the duration of electrocardiogram monitor-
ing. This was shown in patients with cryptogenic stroke who 
underwent electrocardiogram monitoring with implantable 
cardiac monitors. Cumulative detection rates of AF increased 
with continued monitoring, increasing from 3.7% at 1 month, 
to 12.4% at 1 year and reaching 30% at 3 years.23
Thus, the burden of AF reaching epidemic levels in 
the 21st century is an ever increasing reality.24 Given 
that population ageing is at least in part attributable to 
improved survival due to implications of evidence-based 
treatment into routine clinical practice, the prevalence 
of comorbidities such as hypertension, coronary artery 
disease, diabetes mellitus, chronic kidney disease, heart 
failure, is also increasing alongside with aging, contrib-
uting to the growing AF burden. These conditions are 
intimately linked to each other, and the rate of their 
coexistence is high.
Hypertension is now the leading cardiovascular risk 
factor to predispose to AF globally. Mechanisms by 
which hypertension predisposes to AF development are 
summarized in the Figure  1. The evidence from multi-
ple cohorts has confirmed a strong association between 2 
conditions (see Table 1) leading to the inclusion of blood 
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MECHANISMS OF AF: FROM HYPERTENSION TO 
ARRHYTHMIA?
Risk factors and pathophysiology of AF have been stud-
ied extensively but definite mechanisms have not yet been 
fully elucidated and those that have are poorly understood. 
AF has a complex origin with multiple pathways of excita-
tion. Notwithstanding epidemiological parallels between 
hypertension and AF, their coexistence is a common clini-
cal scenario, but other cardiovascular and noncardiovascular 
conditions can also be causative of arrhythmia.6 Irrespective 
of the underlying condition, a combination of diverse (but 
often interplaying) pathways lead to structural and functional 
changes followed by electrophysiological, contractile, and 
architectural disturbances within the left atrium, commonly 
defined as atrial cardiomyopathy and serve together as an 
arrhythmogenic substrate for AF initiation and persistence.25
To be responsible for arrhythmia development, there needs 
to be focal ectopic firing occurring from the triggered activ-
ity (early or, more frequently, delayed after depolarizations) 
and re-entry cycles formation, maintained by shortened 
atrial refractoriness, slowed conduction, and unidirectional 
blocks. These include structural remodeling, particularly left 
atrial fibrosis; dysfunction of autonomic nervous system; ion 
channel dysfunction; and calcium handling abnormalities.6
Structural remodeling
Structural remodeling is essential for arrhythmia ini-
tiation and perpetuation in the majority of AF cases. 
The mechanisms of structural remodeling both in the left 
atrium and left ventricles have been reviewed recently.26 
Diffuse accumulation of fibrotic tissue, e.g., collagen fibers 
and fibroblasts, in the extracellular matrix of atrial myocar-
dium, is the hallmark of structural remodeling. Moreover 
cardiac fibroblasts and other cellular populations (e.g., 
progenitor cells, endothelial cells, etc.) via epithelial to 
mesenchymal transitions, can switch to a more profibrotic 
phenotype, the myofibroblast, with a higher capacity to pro-
liferate and synthesize components of extracellular matrix.26
Apart from being the major source of collagen synthesis 
in the heart, the myofibroblasts also play roles in the release 
of a range of signalling molecules (including the upregula-
tion of proinflammatory cytokines). Furthermore, there is 
direct involvement of cardiac fibroblasts/myofibroblasts in 
atrial arrhythmogenesis due to electrical coupling with car-
diomyocytes, by interference with impulse propagation and 
slow conduction. Subsequently, myofibroblasts may cause 
reduction in cardiomyocytes resting membrane potential 
due to leakage of cardiomyocyte electrical current, fluctua-
tions in action potential duration, appearance of delayed 
after depolarisations, leading to ectopic activity.6,27
Overall, turnover of extracellular matrix (like collagen 
synthesis) and degradation, as well as cardiac fibroblast 
proliferation and dedifferentiation are subject to multiple 
external influences, for example, inflammatory cytokines, 
reactive oxygen species, and hemodynamic load (Figure 2). 
However, the main effector for structural remodeling is the 
rennin–angiotensin axis activation, specifically angioten-
sin II.5,26 Profibrotic effects of angiotensin II are largely 
mediated by the transforming growth factor beta 1 that 
via Smad pathway upregulates expression of particular 
genes, as well as increased aldosterone production, acti-
vation of nicotinamide adenine dinucleotide phosphate 
oxidase, increased inflammatory responses, and apopto-
sis.26,28 Interestingly, transforming growth factor beta 1 is 
associated with a minor but significant increase in the risk 
of incident AF (standard mean difference 0.67; 95% confi-
dence interval [CI] 0.29–1.05 when assessed as continuous 
variable; odds ratio 1.01, 95% CI 1.01–1.02, when assessed 
as categorical variable).29
Recently, thrombin via protease-activated receptors pro-
motes fibrotic, hypertrophic, and inflammatory responses in 
atrial fibroblasts, for example, the expression of transform-
ing growth factor beta 1 and monocyte chemoattractant pro-
tein-1 expression are upregulated as well as incorporation of 
3-hydroxyproline was increased suggesting enhanced col-
lagen synthesis by fibroblasts.30 The latter changes translate 
into higher AF inducibility and complexity of the AF sub-
strate. Of note, thrombin inhibition with dabigatran resulted 
in reduced alpha-smooth muscle actin expression (marker 
of transition of cardiac fibroblasts to myofibroblasts) and 
endomysial fibrosis.30 Given that AF is associated with acti-
vation of coagulation and represents hypercoagulable state, 
these experimental findings are intriguing.
Finally, the atrial myocardium is more prone to develop 
fibrosis compared to ventricles.31,32 Also, AF itself augments 
structural remodeling in the left atrium closing the vicious 
cycle and promoting arrhythmia progression to persistent 
and chronic presentation.5,33
Figure  1. Association between hypertension and AF, and impact on 
outcomes. Abbreviations: AF, atrial fibrillation; DC, direct current cardio-
version; LV EF, left ventricular ejection fraction; PVI, pulmonary vein isola-
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Autonomic dysregulation
Dysregulation in the autonomic nervous system also con-
tributes to the development of substrate for AF, the onset 
of arrhythmia and its maintenance. The left atrium has an 
extensive neural network of sympathetic and parasympa-
thetic fibers, which form nerves, ganglia, and plexi, accu-
mulating data from the baroreceptors, chemoreceptors, 
and mechanical stress receptors, located in the kidneys, 
major arteries (e.g., aorta, carotid bodies), and heart itself.34 
Indeed, arrhythmia onset was shown to be triggered by the 
synchronous increased sympathovagal discharge or fluc-
tuations in autonomic tone35,36; when driven by strenuous 
physical activity or in patients with structural heart disease 
sympathetic flow contributes,37 while vagal influences may 
be amenable for AF in patients with no evidence of struc-
tural heart disease, i.e., lone AF.34
What are the effects of sympathetic and parasympathetic 
system on atrial electrophysiology? Sympathetic activation 
via β1-adrenergic receptors leads to cellular calcium over-
load due to increased calcium influx via l-type calcium 
channels as well as release of calcium from the sarcoplasmic 
reticulum via ryanodine receptors during diastole. Excess of 
calcium is removed via sodium–calcium exchanger with a 
3 (Na+) to 1 (Ca2+) ratio, generating electrical current suf-
ficient for occurrence of delayed after depolarisations. With 
respect to action potential, the influence of sympathetic flow 
may vary with the plateau phase remaining unchanged or 
reduced. This is due to synergistic effect of increased l-type 
calcium current and potassium currents (ultra-rapid delayed 
rectified current, slow delayed rectified current, and acetyl-
choline-dependent current).34
Effects of parasympathetic system are mediated via mus-
carinic receptors and in contrast to effects of sympathetic 
system are associated with definite shortening of action 
potential duration and hence, decreased refractoriness due 
to inhibition of l-type calcium current and activation of 
acetylcholine-dependent potassium current.34,38 With the 
onset of arrhythmia further shortening of action potential 
occurs because of autoprotective limitation of calcium entry 
to cells, that is activated as a result of calcium overload due 
to the high atrial activation rate. Ectopic activation is further 
supported with the spontaneous calcium release from the 
sarcoplasmic reticulum.34
Effect of hypertension on AF substrate
Are there similarities between the pathogenesis of AF and 
hypertension? A close relationship is apparent with respect to 
atrial fibrosis, given that hypertension may cause substantial 
structural changes in the left atrium.25 Persistent hyperactiva-
tion of the rennin–angiotensin–aldosterone axis is one of the 
key mechanisms in the development of arterial hypertension 
with changes observed both in vascular beds and myocardium 
as well as other target organs, including vasoconstriction, cel-
lular proliferation and hypertrophy, cells uncoupling, apopto-
sis, and fibrosis.39 Moreover, renin–angiotensin–aldosterone 
system activation is associated with increased sympathetic 
flow and vice versa, sympathetic activation enhances renin 
synthesis in the juxtaglomerular cells.40
Table 2. Clinical scores to assess risk of AF development
CHARGE-AF86 FHS AF risk score98 ARIC AF risk score88
Age (5-year increment) Age (5-year increment, range 45–≥85) Age (5-year increment, range 45–64)
Race (White vs. African Americans) Body mass index (≥30 vs. <30 kg/m2) Race (Black vs. White)
Height (10 cm increment) Systolic blood pressure (≥160 vs. <160 mm Hg) Height (164–<173 cm or ≥164 cm vs.<164 cm)
Weight (15 kg increment) Treatment for hypertension (Yes vs. No) Systolic BP (20 mm Hg increment, range 
<100–≥160)
Systolic BP (20 mm Hg increment) PR interval (160–199 or ≥200 ms vs. <160 ms) Hypertension medication use (Yes vs. No)
Diastolic BP (10 mm Hg increment) Significant cardiac murmur by years of agea 
(5-year increment, range 45–≥85)
Smoking status (Former or Current vs. Never)
Smoking (current) Heart failure by years of age (5-year increment, 
range 45–84)
Precordial murmur (Yes vs. No)
Antihypertensive medication use  
(Yes vs. No)
Left atrial enlargement (ECG based, Yes vs. 
No)
Diabetes (Yes vs. No) Left ventricular hypertrophy (ECG based, Yes 
vs. No for White race)
Heart failure (Yes vs. No) Diabetes mellitus by years of age (5-year 
increment, range 45–64)
Myocardial infarction (Yes vs. No) Heart failure (Yes vs. No)
Left ventricular hypertrophy (ECG based, 
Yes vs. No)
Coronary heart disease by years of age (5-year 
increment, range 45–64)
PR Interval (<120 or >199 vs. 120–199)
Abbreviations: ARIC, Atherosclerosis Risk In Communities; BP, blood pressure; CHARGE, Cohorts for Heart and Aging Research in Genomic 
Epidemiology; ECG, electrocardiogram; FHS, Framingham Heart Study.
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Substantial data linking electrical, structural, and auto-
nomic remodeling in hypertension and AF have been derived 
from studies on renal sympathetic denervation in animal 
experiments (Table  3) and human studies (Table  4). Early 
data obtained in the first human studies and animal experi-
ments show an overall favorable effect of renal sympathetic 
denervation on electrophysiological parameters, which 
might affect AF inducibility and sustainability that translated 
into decreased recurrence rate in AF patients (Tables 3 and 
4). However, there is still inconsistency between studies and 
criticisms due to study design and small number of patients 
involved. Thus, clinical trials that address renal sympathetic 
denervation as an complementary procedure to pulmonary 
vein isolation have started.41
When switching from the systemic effects of sympa-
thetic and rennin–angiotensin–aldosterone system activa-
tion to simple hemodynamic fluctuations as a link between 
hypertension and AF, it is apparent that left ventricular 
diastolic dysfunction (associated with myocardial hyper-
trophy caused by hypertension) as well as arterial stiffening 
due to aging, hypertension, and other risk factors all lead to 
increased left ventricular filling pressures, and retrograde 
mechanical overload and stretching of left atrium (Figure 1). 
This is supported with both experimental and clinical data. 
In various hypertension models, Lau et al. observed progres-
sive biatrial hypertrophy, left atrial dysfunction, and greater 
AF inducibility along with significant conduction slowing. 
This coupled with inflammatory cell infiltration and increased 
interstitial fibrosis resulted in longer and more fractionated 
AF episodes. Some electrical and structural changes became 
apparent as early as in 5 weeks after the onset of hyperten-
sion, some appeared later, but progressive atrial remodeling 
at a background of hypertension is indisputable.42,43
Examination of large cohort data from the Framingham 
Heart Study show higher augmentation index (hazard ratio 
[HR] 1.16; 95% CI 1.02–1.32), central pulse pressure (HR 
1.14; 95% CI 1.02–1.28), and lower flow-mediated dilation 
(HR 1.27; 95% CI 0.63–0.99) to be associated with increased 
risk of incident AF.44 Echocardiographic Doppler indices of 
left ventricular diastolic dysfunction are predictive of AF 
onset too.45,46
PROGNOSTIC IMPACT OF HYPERTENSION IN AF
AF may have a variety of implications with respect to 
patient prognosis. Participants from the Cardiovascular 
Health Study had poorer outcomes when AF was present 
at baseline or developed during follow-up, for example, 
Figure 2. Simplified scheme of the profibrotic pathways at the tissue and cellular levels. Abbreviations: AKT, protein kinase B; AngII, angiotensin II; AT1R, 
AngII type 1 receptor; AR, aldosterone receptor; Ca2+, calcium; COL1A1, gene encoding α1 type I collagen; COL1A2, gene encoding α2 type I collagen; 
COL3A1, gene encoding α1 type III collagen; CTGF, connective tissue growth factor; ECM, extracellular matrix; EGF, epidermal growth factor; EGFR, EGF 
receptor; ERK, extracellular signal-regulated kinase; ET-1, endothelin-1; ETAR, type A ET-1 receptor; gp130, glycoprotein 130; HIF-α, hypoxia inducible 
factor α; JAK, Janus kinase; JNK, c-jun N-terminal kinase; IGF, insulin-like growth factor; IGFR, IGF receptor; IL6, interleukin 6; IL-6R, IL-6 receptor; LOX, lysyl 
oxidase; MAPK, mitogen-activated protein kinase; NADPH, reduced nicotinamide adenine dinucleotide phosphate; NADPHox, nicotinamide adenine 
dinucleotide phosphate oxidase; NFκB, nuclear factor kappa B; p38, protein 38 (member of MAPK, mitogen-activated protein kinases); PAR, protease-
activated receptor; PDGFR, platelet derived growth factor; PDGFR, PDGF receptor; PI3K, phosphoinositide 3-kinase; Rac1, Ras-related C3 botulinum toxin 
substrate 1; RANK, receptor activator of NFκB; RANKL, RANK ligand; ROS, reactive oxygen species; SAPK, stress-activated protein kinase; Smad, transcrip-
tional factor, named by fusion of C. elegans Sma protein and Drosophila Mad (mothers against decapentaplegic) protein; STAT, signal transducer and 
activator of transcription; TAK1, TGF-β1 activated kinase 1; TβR, TGF-β1 receptor (type I and type II); TGF-β1, transforming growth factor β1; TNFα, tumor 
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Table 3. Overview of studies addressing effect of renal sympathetic denervation on AF substrate and arrhythmia inducibility in animal 
experiments
Ref. Modela
Autonomic and electrical 
















↓ Antegrade Wenckbach 
point
↓ Plasma NE
↓ Plasma renin and aldosterone
↓ Angiotensin II, aldosterone, 
hs-CRP, and IL-6 in atrial 
myocardium










↑ AV node effective 
refractory period
↓ Antegrade Wenckebach 
point





OSA (repetitive NTP maneuvers)
↓ Spontaneous APC ↓ Plasma renin activity and 
aldosterone
↔ Angiotensin II, aldosterone, 11β- 
HSD2, and MR protein expression 
in atrial myocardium.
↔ NADPH oxidase activity, Prx-SO3 
level, redox state of GSH







↓ TH-positive sympathetic 
nerve staining
↓ Transcardiac NE levels
↓ NGF expression
↓ AF cycle length
↓ AF complexity.
↑ Conduction velocity
↔ Expression of β1 and β2- 
adrenergic receptors in 
the atrium







↓ TH- and GAP43- positive 
nerves
↓ AERP shortening
↓ Plasma Angiotensin II and 
aldosterone
↓ ANP, TNF-α, and IL-6 in atrial 
myocardium
↓ Upregulation of caspase-3, bax, 
and Cx40
↔ Cx43






Heart failure (RV tachypacing)








↑ AF cycle length
↓ AERP dispersion
↓P-wave duration and 
dispersion
↓ Fibrosis and ultrastructural 
changes







NA ↓ Collagen volume fraction
↓ Collagen I, CTGF and TGF-β1 
protein and expression in atrial 
myocardium














↓ AERP shortening ↓ Atrial interstitial fibrosis
↓ BNP, Angiotensin II, TNF-α, 
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ischemic stroke (HR 1.98, 95% CI 1.63–2.39), coronary heart 
disease (HR 1.76, 95% CI 1.54–2.03), myocardial infarction 
(HR 1.40, 95% CI 1.14–1.71), heart failure (HR 3.18, 95% CI 
2.78–3.64).47 Similar evidence comes from a large primary 
care database in the United Kingdom that included over 4 
million adults aged 30–90  years, where AF was associated 
with ischemic heart disease (HR 2.52, 95% CI 2.23–2.84), 
heart failure (HR 3.80, 95% CI 3.50–4.12), ischemic stroke 
(HR 2.72, 95% CI 2.19–3.38), hemorrhagic stroke (HR 2.22, 
95% CI 1.60–3.08), chronic kidney disease (HR 1.42, 95% CI 
1.31–1.54), peripheral arterial disease (HR 2.09, 95% CI 1.73–
2.53), and vascular dementia (HR 1.57, 95% CI 1.14–2.17).48
Despite advances in diagnosis and treatment mortality 
from causes associated with AF remains high and has been 
shown to increase over past decades with age-standardized 
mortality rates rising from 70.6 to 107.1 per 100,000 of pop-
ulation; also, there was a 2.0% annual percent increase in 
1999–2009, and to 4.5% up to 2014 in the United States.49 
This rise in AF-associated mortality particularly affected 
younger subjects compared to the whole AF population that 
is represented by elderly people, e.g., 3.7% and 7.3% before 
and after year 2010, respectively.49
How we best manage AF patients co-presenting with 
hypertension to improve patient outcomes is subject to much 
discussion. Hypertension is known to be an independent risk 
factor for range of cardiovascular complications while blood 
pressure reduction is associated with lower risk of adverse 
events.50–52 It is beyond the scope of current review to analyse 
Table 4. Overview of studies addressing effect of renal sympathetic denervation on AF substrate and clinical course in humans






2 (14%) pts had AF history
14 6 months ↓ P-wave duration
↑ Atrial global conduction velocity
↓ Fractionated electrograms
↓ Diffuse ventricular fibrosis  
(MRI-based assessment)
↔ LA size
↔ Global tissue voltage





Severe treatment-resistant HTNb 
and symptomatic drug-refractory 
paroxysmal/ 
persistent AF
27 1 year 69.2% vs. 28.6% AF-free pts 




Pooled analysis of 2 studies—moderate 
and severe treatment-resistant HTNb 
and symptomatic drug-refractory 
paroxysmal/ 
persistent AF
86 1 year 63.4% vs. 41.0% AF-free pts. 
in PVI with RSD vs. PVI-only 
group, respectively
HR 0.45, 95% CI 0.23–0.86 




Pts with AF history excluded
66 6 months ↓ LAVI (independently of SBP)
↓ APC (independently of LA size)
↑ = increased; ↓ = reduced; ↔ = not different as a result of RSD. Abbreviations: APC, atrial premature contractions; AF, atrial fibrillation; BP, 
blood pressure; HTN, hypertension; LA, left atrium; LAVI, left atrial volume index; MRI, magnetic resonance imaging; pts, patients; PVI, pulmo-
nary vein isolation; RSD, renal sympathetic denervation; SVT, supraventricular tachycardia.
aTreatment-resistant hypertension was broadly defined as BP greater than target despite concurrent use of diuretic and at least 2 antihyper-
tensive drugs at adequate doses belonging to different classes.
bModerate treatment-resistant hypertension was defined as poor control by antihypertensive drugs with a BP range ≥140/90 to <160/100 mm 
Hg; severe—BP ≥160/100 mm Hg.
Ref. Modela
Autonomic and electrical 




Acute atrial ischemia / infarction 
(coronary occlusion)
↓ Sympathetic discharges
↓ NE and EPI in the atrial 
myocardium
NA ↓
↑ = increased; ↓ = reduced; ↔ = not different. Abbreviations: 11β-HSD2, 11-β-hydroxysteroid-dehydrogenase-2; AERP, atrial effective refrac-
tory period; APC, atrial premature contraction; AF, atrial fibrillation; BCL-2, B-cell lymphoma gene 2; CTGF, connective tissue growth factor; 
GAP43, growth-associated protein 43; GSH, glutathione; LSG, Left stellate ganglion; MR, mineralocorticoid receptor; NADPH, nicotinamide 
adenine dinucleotide phosphate; NGFβ, nerve growth factor beta; NTP, negative tracheal and thoracic pressure; OSA, obstructive sleep apnea; 
Prx, peroxiredoxin; RAP, rapid atrial pacing; RSD, renal sympathetic denervation; TH, tyrosine hydroxylase; TUNEL, terminal deoxynucleotidyl 
transferase dUTP nick end labeling.
aRegimens of pacing to induce AF varied between studies (e.g., burst, intermittent, short-term or long-term pacing).
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Figure 3. Decision pathway for stroke prevention in patient with hypertension and possible/newly diagnosed nonvalvular AF. For the CHA2DS2-VASc, 
HAS-BLED, and SAMe-TT2R2 see Table 5. Abbreviations: AF, atrial fibrillation; AHRE, atrial high rate episode (defined as episodes >5–6 minutes duration 
and heart rate of >180 bpm detected by an implanted device); BP, blood pressure; ECG, electrocardiogram; NOAC, nonvitamin K oral anticoagulant; OAC, 
oral anticoagulation; VKA, vitamin K antagonist.
Table 5. Stroke and bleeding risk stratification with the CHA2DS2-VASc and HAS-BLED scores, and choice of OAC with the SAMe-TT2R2 
score
CHA2DS2-VASc122 Score HAS-BLED123 Score SAMe-TT2R269 Score
CHF (moderate-to-severe LV systolic 
dysfunction with LV EF ≤40% 
or recent decompensated heart 
failure requiring hospitalization)
1 Hypertension (systolic blood 
pressure >160 mm Hg)
1 Sex category (i.e., female gender) 1
Hypertension 1 Abnormal renal or liver 
function
1 or 2 Age <60 years 1
Age ≥75 years 2 Stroke 1 Medical history (≥2 of the 
following: hypertension, diabetes 
mellitus, CAD/MI, PAD, CHF, 
previous stroke, pulmonary, 
hepatic or renal disease)
1
Diabetes mellitus 1 Bleeding tendency or 
predisposition
1 Treatment with interacting drugs 
(e.g., amiodarone)
1
Stroke/TIA/SE 2 Labile INRs (if on warfarin) 1 Tobacco use (within 2 years) 2
Vascular disease (prior MI, PAD, or 
aortic plaque)
1 Age (e.g., >65, frail condition) 1 Race (i.e., non-Caucasian) 2
Aged 65–74 years 1 Drugs (e.g., concomitant 
antiplatelets or NSAIDs) or 
alcohol excess/abuse
1 or 2
Sex category (i.e., female gender) 1
Maximum score 9 Maximum score 9 Maximum score 8
Abbreviations: CAD, coronary artery disease; CHF, congestive heart failure; INR, international normalized ratio; LV, left ventricular; MI, myo-
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all possible reciprocal relationships between AF, hypertension, 
and their respective complications. However, we focus on the 
impact of hypertension on stroke and systemic thromboem-
bolism in AF and rhythm control management in AF.
Stroke prevention in AF
Prevention of stroke and other thromboembolic events is 
the principal component of AF management given that AF 
is associated with 5-fold elevated risk of stroke overall. Albeit 
AF confers procoagulant state itself stroke risk is largely 
determined by co-presenting stroke risk factors.53 Oral anti-
coagulation with either vitamin K antagonists or nonvitamin 
K antagonists oral anticoagulant should therefore be consid-
ered in patients with at least 1 additional stroke risk factor1,54 
given that even a single stroke risk factor is associated with 
significantly increased risk.55,56
Hypertension is a well-established stroke risk factor not 
only in AF patients but also in patients with sinus rhythm.57 
In the large Swedish nation-wide AF cohort study presence 
of hypertension was shown to be associated with 19%; 95% 
CI 12–25% greater risk of ischemic stroke and 17%; 95% CI 
11–22% greater risk of combination of ischemic stroke, tran-
sient ischemic attack, and systemic embolism.58 Hypertension 
has been therefore incorporated into various stroke risk assess-
ment schemes in line with other risk factors, including the 
guideline recommended CHA2DS2-VASc score (Table 5).1,59
Bleeding risk, along with AF-related stroke risk, must be 
evaluated in patients suitable for oral anticoagulant.60 There 
are a range of factors which put patients at high risk of bleed-
ing. Importantly, many risk factors confer both increased 
stroke and bleeding risk,61 but many of them are also modifi-
able factors, hence a high bleeding risk score is not to rule out 
the use of oral anticoagulation but to highlight the importance 
of risk factor management. Indeed, uncontrolled hyperten-
sion is one of the independent risk factors for development 
of intracranial hemorrhage (HR 1.32, 95% CI 1.15–1.52) and 
major bleeding (HR 1.25, 95% CI 1.16–1.33).58 Bleeding risk 
assessment using the HAS-BLED score (Table  5), includes 
uncontrolled hypertension (defined as blood pressure above 
160 mm Hg) as one of the risk factors for bleeding.1,53,59
In the latest guidelines, nonvitamin K antagonists oral 
anticoagulants are recommended as first-line treatment in 
patients with AF requiring OAC.62 Preference to nonvitamin 
K antagonists oral anticoagulants has been given in antico-
agulation-naïve patient given their overall advantages over 
warfarin therapy as evidenced from trials and real-world 
data together with favorable pharmacokinetics and pharma-
codynamics63–67; however, warfarin is a reasonable alterna-
tive, particularly when well managed and time in therapeutic 
range is high.1,54,62,68 Many factors may interfere with the 
quality of anticoagulation control, including comorbidity 
and requirement to take many drugs.69,70
To avoid a trial period of vitamin K antagonists in the 
anticoagulation-naïve patients and aid decision making with 
respect to choice of oral anticoagulation the SAMe-TT2R2 
score (Table 5) was developed and validated to distinguish 
patients who are capable of reaching the required time in 
therapeutic range with warfarin.69,71
Thus, AF and hypertension, stroke and bleeding risks, and 
even anticoagulation management are closely interlaced. 
Blood pressure control is an essential component of AF 
management. A schematic pathway for stroke prevention in 
the hypertensive patients with diagnosed or clinically sus-
pected AF is shown in the Figure 3.
Rhythm control therapy in AF and hypertension
Rhythm and rate control strategies appeared to have 
similar effect in term of patients outcomes. The main advan-
tage of a rhythm control strategy would be in symptomatic 
patients with AF where they are treated with the antiar-
rhythmic drugs or referred to either direct current cardio-
version, catheter ablation of AF or both at different stages of 
the clinical course of this arrhythmia.1 Given that hyperten-
sion contributes to structural and electrical remodeling in 
AF, it appeared to be predictive of AF recurrence after sinus 
rhythm restoration by either means. Recent studies on effect 
of hypertension on AF ablation outcome arrhythmia recur-
rence are summarized in Table 6.
However, approximately 30% of AF patients are asymp-
tomatic and how best to treat this cohort of patients is of 
growing concern. A  proportion of patients are fortunate 
enough to have AF detected by chance, often due to rou-
tine medical examinations for other reasons. The absence of 
symptoms does not remove or reduce the risk of associated 
Table 7. Clinical scores for prediction of presence of AF substrate (DR-FLASH), onset of AF after atrial flutter ablation (HATCH), and 
freedom from AF after AF ablation (CAAP-AF)
DR-FLASH84 Score HATCH83 Score CAAP-AF85 Score
DM 1 Hypertension 1 Coronary artery disease 1
Renal dysfunction (eGFR  
<90 ml/min/1.73 m2)
1 Age ≥75 years 1 Atrial diameter 0 to 4
Persistent AF 1 Transient ischemic attack or stroke 2 Age 0 to 3
LA diameter >45 mm 1 Chronic obstructive pulmonary 
disease
1 Persistent or long-standing 
AF
2
Age >45 years 1 Heart failure 2 Antiarrhythmics failed 0 to 2
Female sex 1 Female gender 1
Hypertension 1 Maximum score 13
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stroke, with this cohort of patients often found to have a 
higher CHA2DS2VASc score than symptomatic patients.22 
Unfortunately, for the vast majority of patients with asymp-
tomatic AF the first opportunity to detect this arrhythmia is 
in the context of an acute stroke.72 One in 5 ischemic strokes 
are attributable to AF, of which greater than 20% AF are 
diagnosed after the stroke event.73
Overall the meta-analysis of Lin et  al. that included 17 
studies revealed a greater risk of postablation AF recurrence 
in hypertensive patients compared to those with normal 
blood pressure (relative risk 1.31, 95%CI 1.13–1.51); how-
ever, there was significant heterogeneity acknowledged.74 An 
earlier meta-analysis did not demonstrate a significant asso-
ciation between hypertension presence and AF recurrence.75
Effectiveness of blood pressure management including 
control of other factors associated with blood pressure 
elevation has to be considered. Indeed, aggressive risk 
factor management that included blood pressure control 
along with weight reduction, blood lipids and glucose con-
trol, sleep-disordered breathing management, smoking 
and alcohol cessation resulted in greater reduction of LA 
volume index and LV hypertrophy compared to control 
subjects. This translates into a higher AF-free survival rate 
compared to conventional treatment.76 Importance of early 
blood pressure control in slowing the rate of adverse remod-
eling seen in the myocardium of hypertensive patients is 
illustrated in the study by Fredersdorf et al.77 They found 
lone AF to be a predictor of LA volume reduction after suc-
cessful pulmonary vein isolation, while hypertension and 
LV hypertrophy interfered with the reverse remodeling.77 
Hypertension is one of independent predictors of over-
all procedural safety as evidenced from large real-world 
observational studies.78
Target organ damage in hypertension is also associated 
with AF recurrence. In the cohort of patients from the Atrial 
Fibrillation Follow up Investigation of Rhythm Management 
(AFFIRM) trial those with normal left ventricular geometry 
experienced a 2-fold longer AF-free period while concentric 
left ventricular hypertrophy was associated with AF recur-
rence in the rhythm control arm (HR 1.49, 95% CI 1.10–
2.01).79 Significant left ventricular diastolic dysfunction 
that is commonly related to myocardial hypertrophy also 
places patients at higher risk of AF recurrence after catheter 
ablation.80
Subsequently, hypertension has been incorporated into 
several decision-making tools to aid rhythm control man-
agement (Table 7). Hypertension was found to be predictive 
of arrhythmia progression from paroxysmal to more sus-
tained types (i.e., persistent or permanent). Among patients 
with paroxysmal AF participating in European Heart Survey 
hypertension was more common in those who developed 
persistent or permanent AF during 1-year follow-up (71% 
vs. 60%, HR 1.52, 95% CI 1.05–2.20).81 This was further 
confirmed in a prospective survey on AF management, the 
RECORD-AF study (odds ratio 1.5, 95% CI 1.1–2.0).82
The hypertension, age ≥75 years, transient ischemic attack 
or stroke, chronic obstructive pulmonary disease, and heart 
failure (HATCH) score was also applied to predict new-onset 
AF after successful ablation of typical atrial flutter. Chen et al., 
2015 observed 39% new-onset AF during 29.1 ± 18.3 months 
follow-up, and the HATCH score was predictive of AF devel-
opment (HR 1.78, 95% CI 1.35–2.32). They also suggested the 
HATCH score of 2 as cut-off for high risk of AF onset (69% 
vs. 27%).83 The diabetes mellitus, renal dysfunction, persistent 
form of AF, LA diameter >45 mm, age >65 years, female sex, 
and hypertension (DR-FLASH) score was developed to detect 
patients with high probability of the low voltage area presence, 
which reflects fibrotic areas in the left atrium, and are known 
to be predictors of AF recurrence after AF catheter ablation. 
Such patients are likely to benefit from additional substrate 
modification, and should be effectively detected therefore. 
The probability for the presence of LA substrate increased by 
a factor of 2.2 (95% CI 1.6–2.9) with each point scored (C sta-
tistic 0.767).84 The risk of AF recurrence after pulmonary vein 
isolation increased by a factor of 1.3 (odds ratio 1.3, 95% CI 
1.1–1.5) with every additional point and was almost 2 times 
higher in patients with a DR-FLASH score >3 (odds ratio 1.7, 
95% CI 1.1–2.8).84 The CAAP-AF score allows prediction of 
AF ablation outcome (freedom from AF after final ablation).85 
Thus, hypertension is an important risk factor that should be 
taken into account when managing AF with a rhythm control 
strategy.
CONCLUSION
Hypertension has a significant role as cardiovascular 
risk factor and has been shown to promote AF. Due to the 
growing prevalence of both conditions their co-presentation 
will be even more common in the future. Targeting blood 
pressure and optimizing its control should therefore be one 
of the major components of AF management to improve 
patient outcomes. The use of nonvitamin K antagonists oral 
anticoagulants where appropriate should be used in paral-
lel in such patients as part of risk factor management as the 
prognosis of AF-related stroke is by far worse than that for 
non-AF related stroke.72
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